Last $5.50 USD
Change Today -0.04 / -0.72%
Volume 203.9K
As of 1:42 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

cymabay therapeutics inc (CBAY) Snapshot

Open
$5.50
Previous Close
$5.54
Day High
$5.59
Day Low
$5.49
52 Week High
07/9/14 - $13.78
52 Week Low
02/3/14 - $5.00
Market Cap
55.7M
Average Volume 10 Days
179.2K
EPS TTM
--
Shares Outstanding
10.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYMABAY THERAPEUTICS INC (CBAY)

Related News

No related news articles were found.

cymabay therapeutics inc (CBAY) Related Businessweek News

No Related Businessweek News Found

cymabay therapeutics inc (CBAY) Details

Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of various therapies for the treatment of gout and metabolic diseases. Its products include Arhalofenate, which is in Phase IIb clinical study for the treatment of gout; MBX-8025, a selective agonist for disorders linked to defects in lipid storage, handling, and utilization, which has completed five Phase I clinical studies and one Phase II clinical study; and MBX-2982, an oral G-protein coupled receptor agonist to treat type 2 diabetes mellitus (T2DM), which has completed four Phase I clinical studies and one Phase II clinical study. Cymabay Therapeutics, Inc. has a strategic alliance with Ortho-McNeil, Inc.; development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products containing halofenate its enantiomers, derivatives, and analogs. Cymabay Therapeutics, Inc. was formerly known as Metabolex, Inc. The company was incorporated in 1988 and is based in Newark, California.

14 Employees
Last Reported Date: 07/17/14
Founded in 1988

cymabay therapeutics inc (CBAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $481.5K
Chief Financial Officer, Principal Financial ...
Total Annual Compensation: $13.8K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $366.0K
Compensation as of Fiscal Year 2013.

cymabay therapeutics inc (CBAY) Key Developments

Cymabay Therapeutics, Inc.(NasdaqCM:CBAY) added to NASDAQ Composite Index

Cymabay Therapeutics, Inc. will be added to the NASDAQ Composite Index.

Cymabay Therapeutics, Inc. Presents at BIO International Convention, Jun-24-2014 10:00 AM

Cymabay Therapeutics, Inc. Presents at BIO International Convention, Jun-24-2014 10:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Cymabay Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 08:00 AM

Cymabay Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Harold E. Van Wart, Chief Executive Officer, President and Director, Sujal Shah, Chief Financial Officer, Principal Financial & Accounting Officer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBAY:US $5.53 USD -0.01

CBAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBAY.
View Industry Companies
 

Industry Analysis

CBAY

Industry Average

Valuation CBAY Industry Range
Price/Earnings 0.1x
Price/Sales -- Not Meaningful
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYMABAY THERAPEUTICS INC, please visit www.cymabay.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.